NATIONWIDE SURVEY OF PALIVIZUMAB FOR RESPIRATORY SYNCYTIAL VIRUS PREVENTION IN JAPANESE CHILDREN WITH CONGENITAL HEART DISEASE

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract:

A questionnaire study was performed to determine the current status of palivizumab prophylaxis against respiratory syncytial virus infection in Japanese children with congenital heart disease <2 years of age. Palivizumab prophylaxis decreased the respiratory syncytial virus hospitalization rate by 42.8%.

Related Topics

    loading  Loading Related Articles